Close Menu

NEW YORK – Biodesix said today that it has signed an agreement with Thermo Fisher Scientific to develop and seek US Food and Drug Administration approval for a sequencing-based lung cancer liquid biopsy diagnostic test.

Under the agreement, Biodesix will generate analytical and clinical data using Thermo Fisher's Ion Torrent Oncomine Pan-Cancer Cell-Free Assay to apply for premarket approval (PMA) from the FDA. The initiative will focus on patients with advanced non-small cell lung cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Mar
18
Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

Mar
29
Sponsored by
Thermo Fisher Scientific

Global genetic surveillance is vital for understanding the evolution of viral pathogens and monitoring for changes in transmissibility, virulence, disease pathology, and impact on the efficacy of diagnostic tests, therapeutics, and vaccines.

Mar
31
Sponsored by
MilliporeSigma

This webinar will outline the development and commercialization journey of a novel CRISPR-based SARS-CoV-2 test.